News

Sweet deal for Symrise
Enlarge image

BusinessGermanyFrance

Sweet deal for Symrise

15.04.2014 - German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

Symrise AG announced that the company has submitted a binding offer and entered into exclusive discussions with the owners of Diana Group, Paris-based private-equity firm Ardian Sàrl, with regards to the acquisition of the French company. With the takeover, Symrise aims to strengthen its activities in the flavour and nutrition markets. The deal is expected to be completed in the third quarter 2014. The German company thus closes the gap on larger rivals like Swiss Givaudan SA and US-American International Flavors & Fragrances Inc.

Diana Group, which is headquartered in Vannes, is a "highly profitable business" for Symrise: the company generated sales of around €425m in 2013, with an EBITDA margin of approximately 21%. Symrise CEO Heinz Jürgen Bertram expressed his satisfaction with the deal: "The proposed acquisition is fully in line with our strategic objective to further accelerate profitable growth. With Diana we will be able to significantly diversify our portfolio for natural ingredients, tap into new business segments, strengthen our raw material supply and meet the requests for traceability from our customers. The planned integration of Diana will create an unparalleled set-up which will offer us new opportunities for profitable growth beyond our current market and establish an excellent position to generate value in the future."

The investment amounts to €1.3bn, for which Symrise has already secured the required bridge financing. The final financing structure will comprise of debt and equity. The acquisition is expected to be fully EPS accretive from 2015 onwards. The proposed transaction is subject to consultation with the worker’s council and to antitrust clearance. Stamford Partners LLP acted as sole financial advisor to Symrise on the transaction.

© eurobiotechnews.eu/um

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

FinancingFrance

25.03.2014 Immunotherapy developer Transgene SA has successfully raised a total of €65.5m via a two-step capital increase – including a rights issue and a private placement.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html?cHash=807fa298e991d514ff878d4f7a870d11&sort=desc

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR91.0%
  • WILEX (D)0.88 EUR51.7%
  • BIOTECH PHARMACON (N)17.50 NOK50.9%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-47.9%
  • GW PHARMACEUTICALS (UK)219.50 GBP-46.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP5900.0%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.7%
  • EVOCUTIS (UK)0.22 GBP-92.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014